WO2006037629A1 - Verwendung von lavendelöl zur prophylaxe und behandlung von neurasthenie, somatisierungsstörungen und von anderen stress-assoziierten erkrankungen - Google Patents
Verwendung von lavendelöl zur prophylaxe und behandlung von neurasthenie, somatisierungsstörungen und von anderen stress-assoziierten erkrankungen Download PDFInfo
- Publication number
- WO2006037629A1 WO2006037629A1 PCT/EP2005/010732 EP2005010732W WO2006037629A1 WO 2006037629 A1 WO2006037629 A1 WO 2006037629A1 EP 2005010732 W EP2005010732 W EP 2005010732W WO 2006037629 A1 WO2006037629 A1 WO 2006037629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lavender oil
- stress
- treatment
- prophylaxis
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Definitions
- the present invention relates to the prophylactic and therapeutic use of lavender oil for the treatment of neurasthenia, somatization disorders and other stress-associated diseases and lavender oil-containing drugs and dietetic foods as well as preparations and capsules as oral dosage forms.
- Neurasthenia is an acquired nervous condition characterized by rapid fatigue, physical weakness, head and body aches, autonomic overexcitability, affectability, memory and concentration deficiency, irritability, mood swings and sleep disorders (Roche Lexikon, Kunststoff, 4th edition 1998).
- Somatization disorder is the presence of multiple, recurrent and frequently changing physical symptoms.
- the symptoms can refer to any part of the body or system of the body.
- Neurasthenia and somatization disorders can be due to a variety of causes, with stress often being a triggering factor.
- the currently available drugs for the treatment of neurasthenia, somatization disorders and other stress-associated diseases include anxiolytics such.
- the effectiveness of these funds is limited. Furthermore, they are also associated with significant side effects. So z.
- the chronic use of benzodiazepines to addiction, while the neuroieptics can cause very unpleasant so-called early or tardive dyskinesia.
- the use of antidepressants often leads to autonomic disorders, such as As dry mouth, tremor, fatigue, or sexual dysfunction to Anorgasmie.
- Real lavender grows as a semi-shrub to about 60 cm high. The range extends from the Canary Islands throughout the Mediterranean to the Middle East. Ingredients are mainly essential oils in the above-ground parts (mainly monoterpenes), as well as caffeic acid and its depside in the leaves described. The essential oils produced from lavender are traditionally used for cosmetic products, but also for therapeutic purposes. B. used in aromatherapy. Thus, lavender oil has antibacterial, antifungal, spasmolytic, sedative and antidepressant effects (HMA Cavanagh et al., (2002), Phytother. Res., 16, 301-308).
- the oral administration of lavender oil in patients with neurasthenia, somatization disorders and / or post-traumatic stress disorder leads to a significant improvement in various disease-related symptoms.
- stress-induced behavioral changes were significantly inhibited by oral administration of lavender oil in animal experiments.
- the oral intake of lavender oil can be used for the therapy of neurasthenia, somatization disorders and stress associated diseases. Such effects have not previously been described for lavender oil and were not expected due to the pharmacological and clinical effects previously known for lavender oil.
- Lavender oil can be prepared by known production processes, preferably by steam distillation of freshly harvested lavender flowers.
- the lavender oil can be bottled in capsules of gelatin, cellulose derivatives, or other suitable materials for encapsulation or as a solution, preferably orally administered.
- the oil with suitable pharmaceutically acceptable excipients such as Medium chain triglycerides, vegetable oils (e.g., sunflower oil, soybean oil, wheat germ oil and others) and filled into capsules. If necessary, the mixture further auxiliaries z. B. stabilizers added.
- suitable pharmaceutically acceptable excipients such as Medium chain triglycerides, vegetable oils (e.g., sunflower oil, soybean oil, wheat germ oil and others) and filled into capsules. If necessary, the mixture further auxiliaries z. B. stabilizers added.
- the dosage is carried out so that 10 mg to 2 g per day, preferably 20 to 500 mg and more preferably 50 to 100 mg lavender oil are supplied.
- Symptom Checklist SCL 90
- STAI State-Trait Anxiety Inventory
- DS Depression Scale
- MBI Maslach Burnout Inventory
- SF-36 36 Item Short Form Survey
- Sleep Diary the patients came to the clinic and were interviewed by a doctor about the symptoms (external assessment) or the patients completed the questionnaires (self-assessment). Changes compared to before and after six weeks of therapy were reviewed with Wilcoxon Signed Rank Rest and were statistically significantly improved for the majority of symptoms.
- the amount of 800 g of lavender oil required to produce about 10,000 capsules is mixed with 1200 g of medium-chain triglycerides in a sealed, inert container (eg stainless steel agitator container) with stirring for 15 minutes. 200 mg of the homogeneous liquid mixture are filled into gelatin capsules using a suitable capsule filling machine. In the case of hard capsules (eg of gelatin or cellulose derivatives), the capsules are closed by a band after being filled. In the case of soft gelatin capsules, the capsules are filled and sealed in one operation.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT05791751T ATE447963T1 (de) | 2004-10-06 | 2005-10-05 | Verwendung von lavendelöl zur prophylaxe und behandlung von somatisierungsstörungen und von posttraumatischer stresserkrankung |
US11/664,884 US20080124410A1 (en) | 2004-10-06 | 2005-10-05 | Use Of Lavender Oil For The Prophylaxis And Treatment Of Neurasthenia, Somatization Disorders And Other Stress-Associated Diseases |
JP2007535081A JP4900962B2 (ja) | 2004-10-06 | 2005-10-05 | 神経衰弱症、身体化障害および他のストレス関連疾患の予防および治療のためのラベンダー油の使用 |
KR1020077009536A KR101291338B1 (ko) | 2004-10-06 | 2005-10-05 | 신경쇠약증, 신체화 장애 및 다른 스트레스-관련 질병의예방 및 치료를 위한 라벤더 오일의 용도 |
CN200580033566.3A CN101068557B (zh) | 2004-10-06 | 2005-10-05 | 薰衣草油用于预防和治疗神经衰弱症、躯体化障碍和其他与压力相关的疾病的用途 |
DE502005008500T DE502005008500D1 (de) | 2004-10-06 | 2005-10-05 | Verwendung von lavendelöl zur prophylaxe und behandlung von somatisierungsstörungen und von posttraumatischer stresserkrankung |
BRPI0516545-8A BRPI0516545A (pt) | 2004-10-06 | 2005-10-05 | uso de óleo de lavanda para a profilaxia e tratamento de neurastenia, distúrbios de somatização e outras doenças associadas ao estresse |
EP05791751A EP1796702B1 (de) | 2004-10-06 | 2005-10-05 | Verwendung von lavendelöl zur prophylaxe und behandlung von somatisierungsstörungen und von posttraumatischer stresserkrankung |
MX2007004104A MX2007004104A (es) | 2004-10-06 | 2005-10-05 | Uso de aceite de lavanda para la profilaxis y el tratamiento de neurastenia, problemas de somatizacion y otras enfermedades asociadas con la tension. |
AU2005291420A AU2005291420B2 (en) | 2004-10-06 | 2005-10-05 | Use of lavender oil for the prophylaxis and treatment of neuro asthenia, somatization disorders and other diseases associated with stress |
CA2582993A CA2582993C (en) | 2004-10-06 | 2005-10-05 | Use of lavender oil for the prophylaxis and treatment of neurasthenia, somatization disorders and other stress-associated diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004048716A DE102004048716A1 (de) | 2004-10-06 | 2004-10-06 | Verwendung von Lavendelöl zur Prophylaxe und Behandlung von Neurasthenie, Somatisierungsstörungen und von anderen stress-assoziierten Erkrankungen |
DE102004048716.2 | 2004-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006037629A1 true WO2006037629A1 (de) | 2006-04-13 |
Family
ID=35448025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/010732 WO2006037629A1 (de) | 2004-10-06 | 2005-10-05 | Verwendung von lavendelöl zur prophylaxe und behandlung von neurasthenie, somatisierungsstörungen und von anderen stress-assoziierten erkrankungen |
Country Status (16)
Country | Link |
---|---|
US (1) | US20080124410A1 (de) |
EP (1) | EP1796702B1 (de) |
JP (1) | JP4900962B2 (de) |
KR (1) | KR101291338B1 (de) |
CN (1) | CN101068557B (de) |
AT (1) | ATE447963T1 (de) |
AU (1) | AU2005291420B2 (de) |
BR (1) | BRPI0516545A (de) |
CA (1) | CA2582993C (de) |
DE (2) | DE102004048716A1 (de) |
ES (1) | ES2333141T3 (de) |
MX (1) | MX2007004104A (de) |
PT (1) | PT1796702E (de) |
RU (1) | RU2406521C2 (de) |
UA (1) | UA91028C2 (de) |
WO (1) | WO2006037629A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2553625C2 (ru) * | 2013-10-02 | 2015-06-20 | Дмитрий Александрович Никифоров | Эфирно-масляная композиция "биозащита" для лечения астенического синдрома у больных с дисциркуляторной энцефалопатией |
EP2946775A1 (de) * | 2014-05-20 | 2015-11-25 | LTS LOHMANN Therapie-Systeme AG | Lavendelöl enthaltendes transdermales therapeutisches System |
ES2597784T3 (es) * | 2014-07-14 | 2017-01-23 | Dr. Willmar Schwabe Gmbh & Co. Kg | Combinación de extracto de raíz de valeriana y aceite de lavanda para utilizar en el tratamiento de trastornos del sueño |
JP7164973B2 (ja) * | 2018-06-12 | 2022-11-02 | エスエス製薬株式会社 | 錠剤組成物 |
DE202019101081U1 (de) | 2019-02-25 | 2019-04-29 | Tim Farkas | Lavendelkaugummi |
IT202200010973A1 (it) | 2022-05-25 | 2023-11-25 | Cristalfarma S R L | Composizione a base di erbali per uso nel trattamento della depressione post-partum |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0891777A1 (de) * | 1997-06-21 | 1999-01-20 | Aktiengesellschaft Bad Neuenahr | Packung auf Basis von Fango und Verfahren zur Herstellung derselben |
GB2355189A (en) * | 1999-08-20 | 2001-04-18 | Yousef Haik Babikian | Herbal preparation |
US20020136788A1 (en) * | 2001-03-23 | 2002-09-26 | Quezada Richard S. | Therapeutic oil composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1025246A (ja) * | 1996-07-11 | 1998-01-27 | Kobayashi Pharmaceut Co Ltd | 催眠剤、催眠性飲食物及び催眠性餌料 |
EP1275308A1 (de) * | 2001-07-13 | 2003-01-15 | The Procter & Gamble Company | Lebensmittelzusammenstellung mit stresslinderenden Eigenschaften für Säugetiere |
EP1411925A1 (de) * | 2001-08-03 | 2004-04-28 | PHARMACIA & UPJOHN COMPANY | 5-arylsulfonyl-indole mit 5-ht6 rezeptor-affinität |
JP2005029513A (ja) * | 2003-07-07 | 2005-02-03 | Kobayashi Pharmaceut Co Ltd | 口息清涼剤およびその製造方法 |
-
2004
- 2004-10-06 DE DE102004048716A patent/DE102004048716A1/de not_active Withdrawn
-
2005
- 2005-10-05 CA CA2582993A patent/CA2582993C/en active Active
- 2005-10-05 KR KR1020077009536A patent/KR101291338B1/ko active IP Right Grant
- 2005-10-05 ES ES05791751T patent/ES2333141T3/es active Active
- 2005-10-05 US US11/664,884 patent/US20080124410A1/en not_active Abandoned
- 2005-10-05 EP EP05791751A patent/EP1796702B1/de active Active
- 2005-10-05 RU RU2007116726/15A patent/RU2406521C2/ru active
- 2005-10-05 UA UAA200703392A patent/UA91028C2/ru unknown
- 2005-10-05 AT AT05791751T patent/ATE447963T1/de active
- 2005-10-05 MX MX2007004104A patent/MX2007004104A/es active IP Right Grant
- 2005-10-05 AU AU2005291420A patent/AU2005291420B2/en active Active
- 2005-10-05 BR BRPI0516545-8A patent/BRPI0516545A/pt not_active Application Discontinuation
- 2005-10-05 PT PT05791751T patent/PT1796702E/pt unknown
- 2005-10-05 WO PCT/EP2005/010732 patent/WO2006037629A1/de active Application Filing
- 2005-10-05 DE DE502005008500T patent/DE502005008500D1/de active Active
- 2005-10-05 CN CN200580033566.3A patent/CN101068557B/zh active Active
- 2005-10-05 JP JP2007535081A patent/JP4900962B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0891777A1 (de) * | 1997-06-21 | 1999-01-20 | Aktiengesellschaft Bad Neuenahr | Packung auf Basis von Fango und Verfahren zur Herstellung derselben |
GB2355189A (en) * | 1999-08-20 | 2001-04-18 | Yousef Haik Babikian | Herbal preparation |
US20020136788A1 (en) * | 2001-03-23 | 2002-09-26 | Quezada Richard S. | Therapeutic oil composition |
Non-Patent Citations (2)
Title |
---|
ALAKBAROV, F.: "Aromatic Herbal Baths of the Ancients", THE JOURNAL OF THE AMERICAN BOTANICAL COUNCIL, vol. 57, 2003, pages 40 - 49, XP002359006 * |
ANONYMOUS: "St. Gallener Ganzheitsmedizin-Fibel", INTERNET ARTICLE, 25 July 2004 (2004-07-25), pages 1 - 14, XP002359007, Retrieved from the Internet <URL:HTTP://WWW.GANZMED.INFO/MEDIZINDB/DEFAULT.ASP?MITTEL=OELE&START=A&ENDE=M> [retrieved on 20051213] * |
Also Published As
Publication number | Publication date |
---|---|
DE102004048716A1 (de) | 2006-04-20 |
ES2333141T3 (es) | 2010-02-17 |
AU2005291420B2 (en) | 2012-03-29 |
PT1796702E (pt) | 2009-11-20 |
BRPI0516545A (pt) | 2008-09-09 |
RU2406521C2 (ru) | 2010-12-20 |
KR20070074580A (ko) | 2007-07-12 |
JP2008515833A (ja) | 2008-05-15 |
EP1796702A1 (de) | 2007-06-20 |
UA91028C2 (ru) | 2010-06-25 |
CN101068557A (zh) | 2007-11-07 |
ATE447963T1 (de) | 2009-11-15 |
RU2007116726A (ru) | 2008-11-20 |
AU2005291420A1 (en) | 2006-04-13 |
EP1796702B1 (de) | 2009-11-11 |
KR101291338B1 (ko) | 2013-07-31 |
CN101068557B (zh) | 2016-05-11 |
CA2582993A1 (en) | 2006-04-13 |
MX2007004104A (es) | 2007-06-14 |
US20080124410A1 (en) | 2008-05-29 |
JP4900962B2 (ja) | 2012-03-21 |
DE502005008500D1 (de) | 2009-12-24 |
CA2582993C (en) | 2013-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60226103T2 (de) | Heilnahrungsmittel | |
EP1414469A2 (de) | Formulierung enthaltend (lyso-) phosphatidylserin zur vorbeugung und behandlung von stresszuständen bei warmblütern | |
EP1796702B1 (de) | Verwendung von lavendelöl zur prophylaxe und behandlung von somatisierungsstörungen und von posttraumatischer stresserkrankung | |
Park et al. | Efficacy and safety of a mixed extract of Trigonella foenum-graecum seed and Lespedeza cuneata in the treatment of testosterone deficiency syndrome: a randomized, double-blind, placebo-controlled clinical trial | |
EP2974733B1 (de) | Kombination von Baldrianwurzelextrakt und Lavendelöl zur Verwendung zur Behandlung von Schlafstörungen | |
CN106036898A (zh) | 一种具有抗疲劳功效的组合物及制备方法和用途 | |
Brendler et al. | Devil’s Claw (Harpagophytum procumbens DC) an evidence-based systematic review by the natural standard research collaboration | |
US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
CN103082283A (zh) | 海藻精油软胶囊及其制备方法 | |
CN107308400B (zh) | 止泻组方中脂肪油在制备治疗小儿腹泻肚脐贴中的应用 | |
AU2012325600B2 (en) | Pharmaceutical composition regulating blood fat and preparation process thereof | |
KR20180126231A (ko) | 혼합 생약 추출물을 유효성분으로 함유하는 뇌신경 보호용 조성물 | |
US6106839A (en) | Ayurvedic composition for the treatment of disorders of the nervous system including Parkinson's disease | |
DE102005046892A1 (de) | Zusammensetzung aus planzlichem Material und Verwendung derselben zur Herstellung eines Medikaments zur Behandlung von Übergewicht, Fettleibigkeit und Fettsucht | |
CN109549193A (zh) | 一种中药复方改善睡眠的保健食品及其制备方法 | |
CN109745422A (zh) | 一种治疗肾阳虚损的中药组合物及其制备方法 | |
CN107595870A (zh) | 一种健脑安神的药物组合物、药物制剂及应用和制备方法 | |
CN110545830A (zh) | 用于局部使用的包含精油的组合物 | |
Funez et al. | Does vitamin D supplementation reduce the rate of asthma exacerbations requiring systemic steroids? | |
EP2548564B1 (de) | Pharmazeutisches Mittel, Ernährung für einen Patienten sowie Verfahren zur Gewichtsreduzierung | |
Nesari et al. | Fenugreek (Methika): Traditional Wisdom and Research Evidences | |
Elion Itou et al. | Possible mechanisms of anti-inflammatory and analgesic effects of the aqueous extracts of Ceiba pentandra Gaertn (Bombacaceae) and Chromolaena odorata L (King and Robinson)(Astéraceae) in rat | |
CN1054523C (zh) | 一种治疗抑郁型精神病的宁神药物组合物 | |
DE202022107141U1 (de) | Zusammensetzung zur Aktivierung und/oder Stimulierung des limbischen Systems, diese enthaltende Kapsel oder Tablette sowie deren Verwendung als Nahrungsergänzungsmittel oder Arzneimittel | |
CN104544168A (zh) | 预防与治疗人体缺铁的保健制剂及其制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005791751 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580033566.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2582993 Country of ref document: CA Ref document number: MX/a/2007/004104 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007535081 Country of ref document: JP Ref document number: 2005291420 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07034649 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077009536 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007116726 Country of ref document: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11664884 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005791751 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11664884 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0516545 Country of ref document: BR |